Ipsen Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Ipsen is de winst gegroeid met een gemiddeld jaarlijks percentage van 23.9%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 1.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 6.2% per jaar. Het rendement op eigen vermogen van Ipsen is 16.5%, en het heeft een nettomarge van 19.3%.

Belangrijke informatie

23.9%

Groei van de winst

24.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	6.2%
Rendement op eigen vermogen	16.5%
Nettomarge	19.3%
Volgende winstupdate	13 Feb 2025

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Ipsen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:IPSE.Y Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	3,435	664	1,157	653
31 Mar 24	3,371	641	1,146	636
31 Dec 23	3,306	617	1,135	619
30 Jun 23	3,282	406	1,105	528
31 Mar 23	3,219	500	1,072	487
31 Dec 22	3,156	593	1,039	445
30 Sep 22	3,053	656	1,007	436
30 Jun 22	2,950	719	975	427
31 Mar 22	2,849	675	946	425
31 Dec 21	2,749	631	916	424
30 Sep 21	2,712	626	923	422
30 Jun 21	2,676	622	931	420
31 Mar 21	2,681	585	951	413
31 Dec 20	2,686	548	972	406
30 Sep 20	2,697	249	986	404
30 Jun 20	2,707	-50	1,000	403
31 Mar 20	2,700	-53	1,010	396
31 Dec 19	2,693	-55	1,021	389
30 Sep 19	2,605	176	1,003	363
30 Jun 19	2,516	406	986	337
31 Mar 19	2,432	397	970	319
31 Dec 18	2,348	388	954	302
30 Sep 18	2,258	365	931	292
30 Jun 18	2,167	343	909	281
31 Mar 18	2,090	307	883	274
31 Dec 17	2,012	270	858	266
30 Sep 17	1,923	243	821	264
30 Jun 17	1,834	217	785	262
31 Mar 17	1,753	221	752	247
31 Dec 16	1,671	226	719	231
30 Sep 16	1,623	229	703	214
30 Jun 16	1,575	233	687	196
31 Mar 16	1,548	211	676	194
31 Dec 15	1,520	189	666	193
30 Sep 15	1,468	165	651	192
30 Jun 15	1,416	140	636	191
31 Mar 15	1,374	147	606	189
31 Dec 14	1,332	154	577	187
30 Sep 14	1,310	155	557	190
30 Jun 14	1,287	156	537	193
31 Mar 14	1,284	149	543	194
31 Dec 13	1,282	142	549	196

Kwaliteitswinsten: IPSE.Y heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (19.3%) IPSE.Y } zijn hoger dan vorig jaar (12.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van IPSE.Y is de afgelopen 5 jaar aanzienlijk gegroeid met 23.9% per jaar.

Versnelling van de groei: De winstgroei van IPSE.Y over het afgelopen jaar ( 63.4% ) overtreft het 5-jarig gemiddelde ( 23.9% per jaar).

Winst versus industrie: De winstgroei IPSE.Y over het afgelopen jaar ( 63.4% ) overtrof de Pharmaceuticals -sector 54.6%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 16.5% ) van IPSE.Y wordt als laag beschouwd.

Ipsen Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma

Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx®

Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Announces New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport (Abobotulinumtoxina) in Five Therapeutic Indications

Ipsen S.A. to Report Fiscal Year 2020 Results on Feb 11, 2021

Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen Announces First Presentation of Results from the Pivotal Phase III CheckMate -9ER Trial

Ipsen Announces the Release of First Efficacy and Safety Data from the Clarinet Forte Study

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden